One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Nuwellis, Inc.
NUWE · NCM · Healthcare · Medical Devices
Current price
$0.67
52-week range
$0.67 - $172.90
Market cap
$2.44M
Balance sheet
Healthy
-1.05x Concerning
Net cash $3.72M. Interest coverage shows how many times profit covers the interest bill.
What stands out
1 Reward
1 Risk
1 rewards · 1 risks
View details ↓What this company does
Nuwellis, Inc.
Nuwellis sells medical devices that help patients manage fluid overload, mainly from heart failure. Their primary source of money comes from selling these Aquadex systems, which are used in hospitals. Understanding how much it costs them to make and sell these devices, their operating margin (the profit left after everyday business expenses), helps show how well they are managing their costs.
How the company got here
Nuwellis, Inc. was founded in 1999 and was formerly known as CHF Solutions, Inc. before changing its name in April 2021. The company has a history rooted in developing and commercializing medical devices for ultrafiltration therapy. Over the years, Nuwellis has focused on innovation and adapting to the evolving needs of the healthcare market, particularly in cardiorenal care. A key turning point was its rebranding to Nuwellis, signaling a renewed focus on its mission to improve patient outcomes through advanced fluid management solutions. The company has also strategically shifted its focus to prioritize the U.S. market, recognizing it as the area of strongest growth and clinical demand for its technologies.
What it actually does
Nuwellis develops, manufactures, and sells medical devices designed to help patients with fluid overload. Their primary technology is the Aquadex SmartFlow system, which is used in hospitals and clinics. This system helps doctors remove excess fluid from patients who have conditions like heart failure and haven't responded well to other treatments, such as diuretics (medications that help the body get rid of excess water). The goal is to improve patient recovery and protect organ function.
Aquadex SmartFlow System
The Aquadex SmartFlow system is Nuwellis's main product and represents its sole reportable business segment. This system is used for ultrafiltration therapy, a process that removes excess fluid from the bloodstream. It's particularly helpful for patients suffering from fluid overload, a condition where the body retains too much fluid, often due to heart failure or kidney problems. The system is designed to be precise and gentle, allowing clinicians to carefully manage the amount of fluid removed, which can help prevent complications and improve patient outcomes. Nuwellis sells this system directly to hospitals and clinics in the United States and through distributors in other countries.
What management is betting on now
Nuwellis's current strategy is centered on expanding the adoption of its Aquadex system, especially in critical care and pediatric settings. They are also working to improve the recurring use of the system's disposable components (circuits) and developing complementary technologies, like kidney function monitoring systems. Management is focused on leveraging their existing commercial infrastructure to bring new, complementary technologies to market efficiently. This includes exploring partnerships and strategic acquisitions to broaden their offerings in cardiorenal and critical care, aiming to provide integrated solutions that improve patient recovery and protect organ function.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q3
$-2.49M
FY2024 Q4
$-1.53M
FY2025 Q1
$-2.54M
FY2025 Q2
$-2.10M
FY2025 Q3
$-3.25M
FY2025 Q4
$-3.04M
FY2026 Q1
$-3.14M
FY2026 Q2
$-3.18M
Revenue
$1.97M
Net income
$-4.83M
Diluted EPS
-26.64
Operating cash flow
$-3.17M
Free cash flow
$-3.18M
Fetching…
Sources
Revenue
$2.40M
Net income
$-4.54M
Diluted EPS
-2.19
Operating cash flow
$-3.11M
Free cash flow
$-3.14M
Fetching…
Sources
Revenue
$2.42M
Net income
$-2.42M
Diluted EPS
35.73
Operating cash flow
$-3.03M
Free cash flow
$-3.04M
Fetching…
Sources
Revenue
$2.22M
Net income
$468.00K
Diluted EPS
0.56
Operating cash flow
$-3.15M
Free cash flow
$-3.25M
Fetching…
Sources
Revenue
$1.73M
Net income
$-12.55M
Diluted EPS
-60.99
Operating cash flow
$-2.10M
Free cash flow
$-2.10M
Fetching…
Sources
Revenue
$1.90M
Net income
$-3.01M
Diluted EPS
-0.69
Operating cash flow
$-2.54M
Free cash flow
$-2.54M
Fetching…
Sources
Revenue
$2.32M
Net income
$-1.47M
Diluted EPS
9.30
Operating cash flow
$-1.50M
Free cash flow
$-1.53M
Fetching…
Sources
Revenue
$2.37M
Net income
$2.36M
Diluted EPS
1.74
Operating cash flow
$-2.47M
Free cash flow
$-2.49M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $0.67
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $3.7M - more cash than debt. Interest coverage -1.1x.
Net debt
$-3.72M
Interest coverage
-1.05x
Nuwellis, Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 4 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
NUWE
BASELINE
Nuwellis, Inc.
Total debt $200.00K Interest coverage -1.05x This is the baseline the peer rows are being compared against.
Total debt $175.34K Interest coverage -12.65x Neither company has much profit cushion over interest right now.
Total debt $505.00K Interest coverage -30.20x Neither company has much profit cushion over interest right now.
Total debt $90.00K Interest coverage -407.95x Neither company has much profit cushion over interest right now.
Total debt $1.82M Interest coverage -1,146.57x Neither company has much profit cushion over interest right now.
What you should know
The case for and against NUWE
1 Reward
1 Risk
Rewards
-
Revenue grew 9.0% last year.
Risks
-
Insider ownership is only 5.0% (peer median: 13.6%).
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
0.00x
Forward P/E
-0.26x
P/B
-0.19x
P/S
0.27x
EV/EBITDA
0.10x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
69.7%
Operating margin
-160.9%
Net margin
-125.6%
ROE
—
ROA
-87.8%
Health
Liquidity and balance-sheet strength
Debt / equity
—
Current ratio
1.97x
Quick ratio
1.36x
Total debt
$200.00K
Total cash
$3.92M
Growth
How the business has been compounding
Revenue TTM
$9.01M
Revenue 5Y CAGR
1.1%
EPS TTM
435.92
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-12.46M
Free CF TTM
$-10.90M
FCF margin
-120.9%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
0.0%
Last ex-div date
—